16. Use of the antibody of any one of claims 1-6 for the manufacture of a medicament to treat a haematological malignancy, wherein said haematological malignancy is B-cell lymphoma, non-Hodgkin's lymphoma, or B-cell chronic lymphocytic leukaemia.

17. Use of the antibody of any one of claims 1-6 for the manufacture of a medicament to treat an autoimmune disease, wherein said autoimmune disease is rheumatoid arthritis or lupus.

18. Use of the antibody according to claim 16, wherein said haematological malignancy is B-cell lymphoma.

19. An antibody according to any one of claims 1-6 for use as a medicament to treat B-cell lymphoma.

~~20. An isolated polynucleotide comprising a sequence that encodes a light chain variable region sequence of SEQ ID NO: 48.~~

~~21~~20. ~~The~~ An isolated polynucleotide ~~of claim 20, wherein said isolated polynucleotide further comprises~~ comprising a sequence that encodes a light chain variable region sequence of SEQ ID NO: 48 and a sequence that encodes a heavy chain variable region sequence of SEQ ID NO: 128.

~~22~~21. ~~The~~ An isolated polynucleotide ~~of claim 20, wherein said isolated polynucleotide further comprises~~comprising a sequence that encodes a light chain variable region sequence of SEQ ID NO: 48 and a sequence that encodes a heavy chain variable region sequence of SEQ ID NO: 129.

~~23~~22. An expression vector comprising the polynucleotide of any one of claims 20-~~22~~21.

~~24~~23. A host cell comprising the expression vector of claim ~~23~~22.

~~25~~24. A method for producing in a host cell an anti-CD20 antibody having an Fc region with modified oligosaccharides and engineered to have increased effector function, said method comprising:

a. culturing a host cell engineered to express at least one nucleic acid encoding a polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity under

conditions which permit the production of said antibody, and which permit the modification of the oligosaccharides present on the Fc region of said antibody; and

b. isolating said antibody;

wherein said antibody is the modified antibody of any one of claims 1-6.

~~26~~25. The method of claim ~~25~~24, wherein said host cell is further engineered to express a nucleic acid encoding a polypeptide having mannosidase II activity.

~~27~~26. The method of claim ~~25~~24 or ~~26~~25, wherein said modified oligosaccharides have reduced fucosylation as compared to non-modified oligosaccharides.

~~28~~27. The method of any one of claims ~~25~~24-~~27~~26, wherein said antibody produced by said host cell has an increased proportion of bisected, non-fucosylated oligosaccharides in the Fc region of said polypeptide.